New diabetes drug HDM1005 enters final testing phase

NCT ID NCT07394114

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial is testing whether the experimental drug HDM1005 can help people with type 2 diabetes control their blood sugar better than a placebo. About 240 adults who have not used diabetes medication for at least 12 weeks will receive either HDM1005 or a placebo injection weekly for up to 52 weeks. The main goal is to see if HDM1005 lowers HbA1c, a key measure of long-term blood sugar control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HDM1005 (an injectable drug for blood sugar control)
What this could lead to
If successful, HDM1005 could offer a new treatment option to help people with type 2 diabetes better manage their blood sugar levels.
What could go wrong
This is a Phase 3 trial, but it is still testing a new drug. It may not prove more effective than existing treatments, and side effects are possible. Results may not apply to all diabetes patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chinese PLA General Hospital

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.